Capricor Therapeutics Inc CAPR:NASDAQ

Last Price$5.00NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/12/22

Today's Change-0.28(5.30%)
Bid (Size)$4.55 (1)
Ask (Size)$5.15 (1)
Day Low / High$4.86 - 5.40
Volume210.7 K

View Pharmaceuticals: Major IndustryPeer Comparison as of 08/12/2022


Capricor Therapeutics Inc ( NASDAQ )

Price: $5.00
Change: -0.28 (5.30%)
Volume: 210.7 K
4:00PM ET 8/12/2022

MediciNova Inc ( NASDAQ )

Price: $2.49
Change: +0.05 (2.05%)
Volume: 37.1 K
4:00PM ET 8/12/2022

Checkpoint Therapeutics Inc ( NASDAQ )

Price: $1.30
Change: +0.04 (3.17%)
Volume: 293.4 K
4:00PM ET 8/12/2022

vTv Therapeutics Inc ( NASDAQ )

Price: $1.29
Change: +0.04 (3.20%)
Volume: 322.6 K
4:00PM ET 8/12/2022

OncoCyte Corp ( NASDAQ )

Price: $0.94
Change: -0.04 (3.65%)
Volume: 197.0 K
4:00PM ET 8/12/2022

Read more news Recent News

Earnings Reaction History: Capricor Therapeutics Inc, 55.6% Follow-Through Indicator, 8.6% Sensitive
12:22PM ET 8/10/2022 MT Newswires

Expected Earnings Release: 08/10/2022, After-hours Avg. Extended-Hours Dollar Volume: $414,144 Capricor Therapeutics Inc (CAPR) is due to issue its...

Capricor Therapeutics Says First Patient Dosed in Phase 3 Trial of CAP-1002 to Treat Duchenne Muscular Dystrophy
10:53AM ET 7/19/2022 MT Newswires

Capricor Therapeutics (CAPR) said Tuesday the first patient has been dosed in the phase 3 trial of CAP-1002 to treat Duchenne muscular dystrophy. The trial...

Capricor Therapeutics Says CAP-1002 Study Data Shows 'Statistically Significant Improvements' to Treat Muscular Dystrophy
7:59AM ET 6/27/2022 MT Newswires

Capricor Therapeutics (CAPR) said Monday data from a study of CAP-1002 in non-ambulant patients with later-stage Duchenne muscular dystrophy show...

-- Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Reports Q1 Loss $-0.32
4:01PM ET 5/10/2022 MT Newswires


Company Profile

Business DescriptionCapricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded on June 17, 1996 and is headquartered in San Diego, CA. View company web site for more details
Address10865 Road to the Cure
San Diego, California 90211
Number of Employees22
Recent SEC Filing08/12/202210-Q
President, Chief Executive Officer & DirectorLinda Marbán
Chief Financial OfficerAnthony Bergmann
Vice President-Research & DevelopmentKristi A. H. Elliott
Vice President-Clinical DevelopmentDaniel Paulson

Company Highlights

Price Open$5.30
Previous Close$5.28
52 Week Range$2.56 - 5.85
Market Capitalization$121.6 M
Shares Outstanding24.3 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement11/08/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.04
Beta vs. S&P 500N/A
Revenue$671.4 K
Net Profit Margin-12,274.40%
Return on Equity-79.44%

Analyst Ratings as of 06/27/2022

Consensus RecommendationConsensus Icon
Powered by Factset